Tvardi Therapeutics (TVRD) Asset Utilization Ratio (2014 - 2025)
Tvardi Therapeutics (TVRD) posted Asset Utilization Ratio of 0.2 for Q1 2025, up 23.8% sequentially from 0.16 in Q4 2024, and up 30.18% YoY from 0.16 in Q1 2024.
Tvardi Therapeutics (TVRD) Asset Utilization Ratio (2014 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Asset Utilization Ratio for 12 years, with the latest figure at 0.2 in Q1 2025.
- Quarterly Asset Utilization Ratio rose 30.18% year-over-year to 0.2 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 0.2 (up 30.18% YoY) and the FY2024 annual result came in at 0.09, down 34.88% from the prior year.
- Asset Utilization Ratio climbed to 0.2 in Q1 2025 per TVRD's latest filing, from 0.16 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.6 in Q3 2021 and troughed at 0.1 in Q4 2021.
- A 5-year average of 0.24 and a median of 0.18 in 2022 frame the typical range for Asset Utilization Ratio.
- The widest YoY moves for Asset Utilization Ratio: up 243.87% in 2021, down 84.84% in 2021.
- Over 5 years, Asset Utilization Ratio stood at 0.1 in 2021, then soared by 116.91% to 0.21 in 2022, then decreased by 17.82% to 0.17 in 2023, then decreased by 5.13% to 0.16 in 2024, then rose by 23.8% to 0.2 in 2025.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.2, 0.16, and 0.14 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 0.20 |
| Dec 31, 2024 | 0.16 |
| Sep 30, 2024 | 0.14 |
| Jun 30, 2024 | 0.14 |
| Mar 31, 2024 | 0.16 |
| Dec 31, 2023 | 0.17 |
| Sep 30, 2023 | 0.17 |
| Jun 30, 2023 | 0.19 |
| Mar 31, 2023 | 0.26 |
| Dec 31, 2022 | 0.21 |
| Sep 30, 2022 | 0.18 |
| Jun 30, 2022 | 0.22 |
| Mar 31, 2022 | 0.11 |
| Dec 31, 2021 | 0.10 |
| Sep 30, 2021 | 0.60 |
| Jun 30, 2021 | 0.52 |
| Mar 31, 2021 | 0.49 |
| Dec 31, 2020 | 0.64 |
| Sep 30, 2020 | 0.17 |
| Jun 30, 2020 | 0.18 |